Progress in the validation of models that could help accelerate the development of novel therapeutics for pain and migraine was reported at the AHS 2022 conference.
Researchers from the US National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS) presented findings from the NIH Helping to End Addiction Long-term (HEAL) Initiative’s Preclinical Screening Platform for Pain (PSPP) program.